SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2025)
SAB Biotherapeutics (SABS) posted Long-Term Debt Issuances of $3.0 for Q3 2025, down 100.0% on a QoQ basis from $138551.0 in Q2 2025, and down 100.0% year-over-year from $615818.0 in Q3 2024.
SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
SAB Biotherapeutics' Long-Term Debt Issuances history runs 6 years deep, the most recent figure standing at $3.0 for Q3 2025.
- Quarterly Long-Term Debt Issuances fell 100.0% year-over-year to $3.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $275849.0 (down 46.54% YoY) and the FY2025 annual result came in at $275849.0, down 46.54% from the prior year.
- Long-Term Debt Issuances was $3.0 for Q3 2025 at SAB Biotherapeutics, down from $138551.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $3.7 million in Q4 2022 and bottomed at -$534863.0 in Q4 2024.
- A 5-year average of $598962.0 and a median of $254913.0 in 2022 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2021 — Long-Term Debt Issuances surged 1693.75% — and 2024, when it sank 308.94%.
- SAB Biotherapeutics' Long-Term Debt Issuances stood at $2.7 million in 2021, then jumped by 39.35% to $3.7 million in 2022, then tumbled by 93.17% to $255989.0 in 2023, then sank by 308.94% to -$534863.0 in 2024, then surged by 100.0% to $3.0 in 2025.
- Business Quant data shows SABS's Long-Term Debt Issuances at $3.0 in Q3 2025, $138551.0 in Q2 2025, and $137295.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.00 |
| Sep 30, 2025 | 3.00 |
| Jun 30, 2025 | 138,551.00 |
| Jun 30, 2025 | 138,551.00 |
| Mar 31, 2025 | 137,295.00 |
| Mar 31, 2025 | 137,295.00 |
| Dec 31, 2024 | -534,863.00 |
| Dec 31, 2024 | -534,863.00 |
| Sep 30, 2024 | 615,818.00 |
| Sep 30, 2024 | 615,818.00 |
| Jun 30, 2024 | 219,649.00 |
| Jun 30, 2024 | 219,649.00 |
| Mar 31, 2024 | 215,382.00 |
| Mar 31, 2024 | 215,382.00 |
| Dec 31, 2023 | 255,989.00 |
| Dec 31, 2023 | 255,989.00 |
| Sep 30, 2023 | 111,893.00 |
| Sep 30, 2023 | 111,893.00 |
| Jun 30, 2023 | 332,585.00 |
| Jun 30, 2023 | 332,585.00 |